S L Meeks

Summary

Affiliation: Children's Healthcare of Atlanta
Country: USA

Publications

  1. pmc Potentiation of thrombin generation in hemophilia A plasma by coagulation factor VIII and characterization of antibody-specific inhibition
    Bhavya S Doshi
    Emory University School of Medicine, Atlanta, Georgia, United States of America
    PLoS ONE 7:e48172. 2012
  2. ncbi request reprint Should hemophilia treaters switch to albumin-free recombinant factor VIII concentrates
    Shannon L Meeks
    Aflac Cancer Center and Blood Disorders Service, Emory University Children s Healthcare of Atlanta, USA
    Curr Opin Hematol 13:457-61. 2006
  3. doi request reprint Abnormalities of prothrombin: a review of the pathophysiology, diagnosis, and treatment
    S L Meeks
    Aflac Cancer Center and Blood Disorders Service, Children s Healthcare of Atlanta and Emory University, Atlanta, GA 30322, USA
    Haemophilia 14:1159-63. 2008
  4. doi request reprint Late immune tolerance induction in haemophilia A patients
    S L Meeks
    Aflac Cancer Center and Blood Disorders Service, Children s Healthcare of Atlanta, Emory University, Atlanta, GA 30322, USA
    Haemophilia 19:445-8. 2013
  5. pmc Non-classical anti-factor VIII C2 domain antibodies are pathogenic in a murine in vivo bleeding model
    S L Meeks
    Department of Pediatrics, Aflac Cancer Center and Blood Disorders Service, Children s Healthcare of Atlanta, Emory University, Atlanta, GA 30322, USA
    J Thromb Haemost 7:658-64. 2009
  6. pmc Epitope mapping of inhibitory antibodies targeting the C2 domain of coagulation factor VIII by hydrogen-deuterium exchange mass spectrometry
    A M Sevy
    AFLAC Cancer and Blood Disorders Center, Children s Healthcare of Atlanta, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA
    J Thromb Haemost 11:2128-36. 2013
  7. pmc Antihuman factor VIII C2 domain antibodies in hemophilia A mice recognize a functionally complex continuous spectrum of epitopes dominated by inhibitors of factor VIII activation
    Shannon L Meeks
    Aflac Cancer Center and Blood Disorders Service, Children s Healthcare of Atlanta, Department of Pediatrics, Emory University, Atlanta, GA, USA
    Blood 110:4234-42. 2007
  8. pmc Nonclassical anti-C2 domain antibodies are present in patients with factor VIII inhibitors
    Shannon L Meeks
    Department of Pediatrics, Aflac Cancer Center and Blood Disorders Service, Children s Healthcare of Atlanta, Emory University, Atlanta, GA30322, USA
    Blood 112:1151-3. 2008

Collaborators

Detail Information

Publications8

  1. pmc Potentiation of thrombin generation in hemophilia A plasma by coagulation factor VIII and characterization of antibody-specific inhibition
    Bhavya S Doshi
    Emory University School of Medicine, Atlanta, Georgia, United States of America
    PLoS ONE 7:e48172. 2012
    ..Therefore, combined fVIII/rfVIIa therapy may provide better hemostatic control than current therapy in some patients with anti-fVIII inhibitors...
  2. ncbi request reprint Should hemophilia treaters switch to albumin-free recombinant factor VIII concentrates
    Shannon L Meeks
    Aflac Cancer Center and Blood Disorders Service, Emory University Children s Healthcare of Atlanta, USA
    Curr Opin Hematol 13:457-61. 2006
    ..To discuss the advantages and disadvantages of the albumin-free recombinant factor VIII concentrates in the treatment of hemophilia A...
  3. doi request reprint Abnormalities of prothrombin: a review of the pathophysiology, diagnosis, and treatment
    S L Meeks
    Aflac Cancer Center and Blood Disorders Service, Children s Healthcare of Atlanta and Emory University, Atlanta, GA 30322, USA
    Haemophilia 14:1159-63. 2008
    ..No purified prothrombin products are available for replacement therapy. Both fresh frozen plasma and prothrombin complex concentrates contain prothrombin and may be used for treatment...
  4. doi request reprint Late immune tolerance induction in haemophilia A patients
    S L Meeks
    Aflac Cancer Center and Blood Disorders Service, Children s Healthcare of Atlanta, Emory University, Atlanta, GA 30322, USA
    Haemophilia 19:445-8. 2013
    ..Two patients are not tolerized. Some patients with haemophilia A and long-standing inhibitors may benefit from ITI...
  5. pmc Non-classical anti-factor VIII C2 domain antibodies are pathogenic in a murine in vivo bleeding model
    S L Meeks
    Department of Pediatrics, Aflac Cancer Center and Blood Disorders Service, Children s Healthcare of Atlanta, Emory University, Atlanta, GA 30322, USA
    J Thromb Haemost 7:658-64. 2009
    ..The pathogenicity of anti-human factor (F) VIII monoclonal antibodies (MAbs) was tested in a murine bleeding model...
  6. pmc Epitope mapping of inhibitory antibodies targeting the C2 domain of coagulation factor VIII by hydrogen-deuterium exchange mass spectrometry
    A M Sevy
    AFLAC Cancer and Blood Disorders Center, Children s Healthcare of Atlanta, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA
    J Thromb Haemost 11:2128-36. 2013
    ..Thus, the ability to quickly map the epitope spectrum of patient plasma with a clinically feasible assay may fundamentally change how clinicians approach the treatment of high-titer inhibitor patients...
  7. pmc Antihuman factor VIII C2 domain antibodies in hemophilia A mice recognize a functionally complex continuous spectrum of epitopes dominated by inhibitors of factor VIII activation
    Shannon L Meeks
    Aflac Cancer Center and Blood Disorders Service, Children s Healthcare of Atlanta, Department of Pediatrics, Emory University, Atlanta, GA, USA
    Blood 110:4234-42. 2007
    ..These results reveal the structural and functional complexity of the anti-C2 domain antibody response and indicate that interference with fVIII activation is a major attribute of the inhibitor landscape...
  8. pmc Nonclassical anti-C2 domain antibodies are present in patients with factor VIII inhibitors
    Shannon L Meeks
    Department of Pediatrics, Aflac Cancer Center and Blood Disorders Service, Children s Healthcare of Atlanta, Emory University, Atlanta, GA30322, USA
    Blood 112:1151-3. 2008
    ..Most of the anti-C2 inhibitor plasmas inhibited the binding of both classical and nonclassical antibodies. These results suggest that nonclassical anti-C2 antibodies contribute significantly to the pathogenicity of fVIII inhibitors...